JP2013543897A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543897A5
JP2013543897A5 JP2013541034A JP2013541034A JP2013543897A5 JP 2013543897 A5 JP2013543897 A5 JP 2013543897A5 JP 2013541034 A JP2013541034 A JP 2013541034A JP 2013541034 A JP2013541034 A JP 2013541034A JP 2013543897 A5 JP2013543897 A5 JP 2013543897A5
Authority
JP
Japan
Prior art keywords
formulation
adrenergic receptor
patient
selective beta
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013541034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061973 external-priority patent/WO2012074856A2/en
Publication of JP2013543897A publication Critical patent/JP2013543897A/ja
Publication of JP2013543897A5 publication Critical patent/JP2013543897A5/ja
Pending legal-status Critical Current

Links

JP2013541034A 2010-11-24 2011-11-22 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法 Pending JP2013543897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41709810P 2010-11-24 2010-11-24
US61/417,098 2010-11-24
PCT/US2011/061973 WO2012074856A2 (en) 2010-11-24 2011-11-22 Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Publications (2)

Publication Number Publication Date
JP2013543897A JP2013543897A (ja) 2013-12-09
JP2013543897A5 true JP2013543897A5 (OSRAM) 2014-12-25

Family

ID=45475499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541034A Pending JP2013543897A (ja) 2010-11-24 2011-11-22 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法

Country Status (17)

Country Link
US (2) US9597531B2 (OSRAM)
EP (1) EP2646012A4 (OSRAM)
JP (1) JP2013543897A (OSRAM)
KR (1) KR20140025312A (OSRAM)
CN (2) CN105832681A (OSRAM)
AU (1) AU2011336869B2 (OSRAM)
BR (1) BR112013012994A2 (OSRAM)
CA (1) CA2815374A1 (OSRAM)
EA (1) EA201270784A1 (OSRAM)
GB (1) GB2485885B (OSRAM)
GE (1) GEP201606551B (OSRAM)
IL (1) IL225879A0 (OSRAM)
MX (1) MX2013005873A (OSRAM)
SG (1) SG190878A1 (OSRAM)
TW (1) TW201231042A (OSRAM)
UA (1) UA111822C2 (OSRAM)
WO (1) WO2012074856A2 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2523667A4 (en) * 2010-01-15 2014-04-02 Lithera Inc LYOPHILIZED CAKE FORMULATIONS
AU2021282582A1 (en) * 2020-06-04 2023-02-02 Curasen Therapeutics, Inc. Forms and compositions of a beta adrenergic agonist

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898330A (en) 1973-08-01 1975-08-05 Squibb & Sons Inc Corticosteroid phosphate salts/neomycin sulfate ophthalmic
US4525359A (en) 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
NZ212204A (en) 1984-06-04 1988-07-28 Merck & Co Inc Growth-promoting compositions containing hydroxylic compounds
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
JPH0696521B2 (ja) 1986-01-31 1994-11-30 千寿製薬株式会社 眼局所投与用眼圧降下剤
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
JP3342484B2 (ja) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
US5314916A (en) 1993-04-19 1994-05-24 Alcon Laboratories, Inc. B2 adrenegic agonists and use thereof in the treatment of glaucoma
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
DE69739085D1 (de) 1996-09-19 2008-12-18 Univ Michigan Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
TW469832U (en) 1997-03-14 2001-12-21 Astra Ab Inhalation device
TR199902615T2 (xx) 1997-03-18 2000-03-21 Basf Aktiengesellschaft Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar.
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0979081A4 (en) 1997-04-30 2003-05-02 Bridge Pharma Inc COMPOSITION AND METHODS USING EUTOMER
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
JPH11106334A (ja) 1997-09-30 1999-04-20 Saitama Daiichi Seiyaku Kk 尿失禁治療剤
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
GB9924992D0 (en) 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
US6936426B2 (en) 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
EP1330636A1 (en) 2000-11-03 2003-07-30 Histotech Aps A device and a method for sectioning of tissue blocks
AU3169702A (en) 2000-12-07 2002-06-18 Yamanouchi Europ Bv Composition for treatment of inflammatory disorders
US20030022856A1 (en) 2001-01-30 2003-01-30 The Regents Of The University Of Michigan Method for sustained release local delivery of drugs for ablation of unwanted tissue
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
MXPA04003879A (es) 2001-10-24 2005-02-17 Pari Gmbh Equipo para la preparacion de una composicion farmaceutica.
US6625078B2 (en) 2002-02-11 2003-09-23 United Memories, Inc. Look-ahead refresh for an integrated circuit memory
DK1476201T3 (da) 2002-02-19 2009-03-30 Resolution Chemicals Ltd Solvent-baseret sterilisering af steroider
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US6643212B1 (en) 2002-04-18 2003-11-04 United Memories, Inc. Simultaneous function dynamic random access memory device technique
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
CA2500065A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004091540A2 (en) 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US20040235922A1 (en) 2003-05-15 2004-11-25 Baile Clifton A. Compositions and methods for inducing adipose tissue cell death
JP2006528228A (ja) 2003-05-22 2006-12-14 アルタナ ファルマ アクチエンゲゼルシャフト サルメテロール及びシクレソニドの組合せ物
SE0302029D0 (sv) 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB2403655A (en) 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
EP1646354A4 (en) 2003-07-22 2010-03-17 Baxter Int SMALL SPHERICAL PARTICLES OF LOW MOLECULAR WEIGHT MOLECULES AND PROCESSES FOR THEIR PREPARATION AND USE
BRPI0414907A (pt) 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US20050075900A1 (en) 2003-10-02 2005-04-07 Arguimbau Vincent C. Method and apparatus for bulk food marking and tracking with supplier rating system
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
JP2007515402A (ja) * 2003-11-20 2007-06-14 アルターアゴン プロプライエタリー リミテッド 哺乳動物および鳥類の体脂肪および体重の減少方法
KR100573828B1 (ko) 2003-12-29 2006-04-26 주식회사 하이닉스반도체 셀데이터의 손실을 방지하기 위한 반도체 메모리 소자
US20080270175A1 (en) 2003-12-31 2008-10-30 Klinger Advanced Aesthetics, Inc. Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures
US20050212152A1 (en) 2004-03-23 2005-09-29 Reens Daniel J System and method for humidifying homes and commercial sites
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス, インコーポレーテッド ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト
AU2004325203A1 (en) 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
WO2006088134A1 (ja) 2005-02-18 2006-08-24 Santen Pharmaceutical Co., Ltd. ステロイド化合物の副作用軽減または回避方法
US20100215710A1 (en) 2005-04-08 2010-08-26 The Regents Of The University Of California Beta-2 Adrenergic Receptor Agonists and Antagonists and Modulation of Wound Healing
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CN1706501A (zh) 2005-05-27 2005-12-14 沈阳药科大学 亲脂性药物环糊精包合物的制备方法
CN101252842A (zh) * 2005-07-14 2008-08-27 利波西拉公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
FR2893845B1 (fr) 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un corticoide et une phase huileuse
CA2631493A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
RU2008142388A (ru) 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
DE102007026979A1 (de) 2006-10-06 2008-04-10 Friedrich Siller Inhalationsvorrichtung
CN101626759B (zh) * 2006-10-17 2014-08-06 利特拉公司 用于治疗甲状腺眼病的组合物和制剂
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
WO2008066775A2 (en) 2006-11-22 2008-06-05 Duncan Diane I Compositions and methods to reduce fat and retract skin
US20080249017A1 (en) 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
JP5627452B2 (ja) 2007-04-24 2014-11-19 アカシア ファーマ リミテッドAcacia Pharma Limited 筋肉減少の治療に使用される薬剤の組合せ
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
PL2170348T3 (pl) 2007-06-22 2017-01-31 Dompé Farmaceutici S.P.A. Tabletki musujące do zastosowania wziewnego
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US7723392B2 (en) 2007-12-03 2010-05-25 Bridge Pharma, Inc. Use of RR/SR-ractopamine
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2523667A4 (en) * 2010-01-15 2014-04-02 Lithera Inc LYOPHILIZED CAKE FORMULATIONS

Similar Documents

Publication Publication Date Title
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
JP2017533972A5 (OSRAM)
JP2013522303A5 (OSRAM)
JP2014098041A5 (OSRAM)
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2013543897A5 (OSRAM)
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
RU2016141314A (ru) Составы разагилина с пролонгированным высвобождением и их применение
KR20140014404A (ko) 국소 지방 조직 치료를 위한 투여 방법 및 제제
ES2265495T3 (es) Uso de tramadol para el retardo de la eyaculacion.
JP2015522033A5 (OSRAM)
JP2020500864A5 (OSRAM)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
RU2014113334A (ru) Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний
KR20120023754A (ko) Ave8062 및 소라페닙을 포함하는 항종양 조합물
JP2016505050A5 (OSRAM)
JP2008534503A5 (OSRAM)
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2008517991A5 (OSRAM)
KR20140025312A (ko) 지방증 및 윤곽 팽창의 미용적 치료를 위한 선택적인, 친유성, 및 지속성 베타 작용제 단일치료 제형 및 방법
RU2017140078A (ru) Косметический способ и его терапевтическое применение для уменьшения объема жировой ткани
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
JP2019535830A5 (OSRAM)